Saturday, January 31, 2015 Last update: 9:03 AM - Covering Large & Obscure Tech Companies Since 1996

Cubist’s Once-daily SIVEXTRO™ (tedizolid phosphate) Available for Physician and Hospital Order in I.V. and Oral Formulations

Companies mentioned in this article: Cubist Pharmaceuticals, Inc.

LEXINGTON, Mass. -- (BUSINESS WIRE) -- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announces SIVEXTRO™ (tedizolid phosphate) indicated for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI) is now available in the U.S. in once-daily I.V. and oral formulations. Approved by the U.S. Food and Drug Administration (FDA) on June 20, 2014, SIVEXTRO addresses ABSSSI caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA)— which has been categorized by the U.S. Centers for Disease Control and Prevention (CDC) as a serious public health threat.

“We are pleased to formally announce the availability of the I.V. version of SIVEXTRO for physician and hospital order in the U.S.,” said Rob Perez, President and Chief Operating Officer of Cubist. “SIVEXTRO oral has been on the market since late June. We believe the features and utility of SIVEXTRO offers physicians an effective option to treat acute bacterial skin and skin structure infections in a number of real-life patient settings—from the hospital to the home.”

The approval of SIVEXTRO marks one of at least four antibiotics Cubist hopes to deliver in support of the Infectious Diseases Society of America challenge to industry and policy makers to develop and approve 10 new antibiotics by 2020.

The EMA has accepted for review Cubist’s Marketing Authorization Application (MAA) for SIVEXTRO, for which the company is seeking approval for the treatment of complicated skin and soft tissue infections (cSSTI). A decision from the European Commission is expected during the first half of 2015.

Clinical studies are also ongoing for the potential use of SIVEXTRO in the treatment of hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP).

About SIVEXTROTM (tedizolid phosphate)

Administered once daily, SIVEXTRO offers an effective, short six-day course of therapy. SIVEXTRO is a novel oxazolidinone with in vitro activity against clinically significant susceptible Gram-positive pathogens including MRSA and is available in both intravenous (I.V.) and oral formulations.

The New Drug Application (NDA) for SIVEXTRO was supported by two global Phase 3 studies, which met primary and secondary endpoints defined by the FDA and the European Medicines Agency (EMA). These studies demonstrated that SIVEXTRO 200 mg administered once daily for six days was statistically non-inferior to 600 mg of linezolid taken twice a day for 10 days. In these studies, the adverse event rates were similar for patients treated with SIVEXTRO and linezolid. Gastrointestinal adverse events (diarrhea, nausea and vomiting) were the most commonly reported in both treatment groups.

SIVEXTRO is one of the first medicines approved in the U.S. that the FDA designated as a Qualified Infectious Disease Product (QIDP) for its indication, ABSSSI, according to the Generating Antibiotic Incentives Now (GAIN) Act of 2012. The QIDP designation qualified SIVEXTRO for certain incentives related to the development of new antibiotics, including a five year extension of Hatch-Waxman exclusivity.

Patients seeking assistance may be eligible for program benefits provided through AccessSIVEXTRO.

Indication and Important Safety Information


SIVEXTROTM (tedizolid phosphate) is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius and Streptococcus constellatus), and Enterococccus faecalis.

Warnings and Precautions

  • Patients with neutropenia: The safety and efficacy of SIVEXTRO in patients with neutropenia (neutrophil counts <1000 cells/mm3) have not been adequately evaluated. In an animal model of infection, the antibacterial activity of SIVEXTRO was reduced in the absence of granulocytes. Alternative therapies should be considered when treating patients with neutropenia.
  • Clostridium difficile–associated diarrhea (CDAD), ranging from mild diarrhea to fatal colitis, has been reported with nearly all systemic antibacterial agents, including SIVEXTRO. Evaluate all patients who present with diarrhea following SIVEXTRO use.
  • Development of drug-resistant bacteria: Prescribing SIVEXTRO in the absence of a proven or strongly suspected bacterial infection or prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria.

Adverse Reactions

The most common adverse reactions for SIVEXTRO are nausea, headache, diarrhea, vomiting, and dizziness.

About Cubist

Cubist Pharmaceuticals, Inc. is a global biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment. Cubist has a growing commitment to global public health through its leadership in the discovery, development and commercialization of novel antibiotics to treat serious and potentially life-threatening infections caused by a broad range of increasingly drug-resistant bacteria. The Company hopes to deliver at least four new antibiotics in support of the Infectious Diseases Society of America (IDSA) goal of 10 new antibiotics by 2020. Cubist expects to invest approximately $400M USD in 2014 on antibacterial R&D and approximately 75% of its employee base is focused on the research, development, commercialization and support of antibiotics. In addition to a focus on Gram-positive pathogens, Cubist’s commitment also includes a focus on Gram-negative pathogens. In this regard, Cubist recently received acceptance of its NDA to the FDA for approval of its investigational antibiotic ceftolozane/tazobactam, being developed to address certain Gram-negative bacteria, for the treatment of Complicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI). The assigned action date for the ceftolozane/tazobactam NDA is December 21, 2014.

Cubist is headquartered in Lexington, Massachusetts, with a central international office located in Zurich, Switzerland. Additional information can be found at Cubist’s web site at Also, connect with Cubist on Twitter @cubistbiopharma and @cubistcareersLinkedIn, or YouTube.

About Acute Skin, Skin Structure and Soft Tissue Infections

Acute bacterial skin and skin structure infections (ABSSSI) are also referred to as complicated skin and soft tissue infections (cSSTI) (in Europe). These infections, which are a significant and growing problem throughout the world, involve deeper tissue or require surgical intervention (e.g., cellulitis, major cutaneous abscesses and infected wounds) or are associated with a significant underlying disease (e.g., diabetes or systemic immunosuppression) that complicates response to therapy. A variety of pathogens may be identified in ABSSSI/cSSTI but the two most common Gram-positive pathogens are Staphylococcus aureus and Streptococcus pyogenes. The significant increase in the incidence of methicillin-resistant Staphylococcus aureus (MRSA) healthcare-associated infections (HAIs), as well as community infections, has resulted in a need for therapies to address serious skin, skin structure and soft tissue infections that are effective against MRSA.

About MRSA

According to the U.S. Centers for Disease Control and Prevention (CDC) “Antibiotic resistance threats in the United States, 2013” report, each year more than two million Americans develop infections from antibiotic-resistant bacteria. One of the serious public health threats identified by the CDC is methicillin-resistant Staphylococcus aureus (MRSA), which continues to be a clinical and economic burden. Based on CDC data, there are approximately 80,000 severe MRSA infections and 11,000 deaths from MRSA in the U.S. per year. The European Centre for Disease Prevention and Control (ECDC) estimates that more than four million European Union (EU) patients acquire healthcare acquired infections (HAIs) annually, resulting in 37,000 deaths and that a large proportion of these deaths are due to the most common multidrug-resistant bacteria, including MRSA. According to the ECDC, MRSA is still the most commonly identified antimicrobial-resistant pathogen in hospitals in many parts of the world, including Europe, the Americas, North Africa, the Middle East, and Asia. Data from the Eurosurveillance journal estimates MRSA infections affect more than 150,000 patients annually in the EU.

Forward Looking Statements

This press release contains forward-looking statements. Any statements contained herein which do not describe historical facts, including but not limited to, statements regarding: the therapeutic and commercial potential of SIVEXTRO and ceftolozane/tazobactam; the expected timing for the European Commission’s decision on our MAA for SIVEXTRO; the anticipated FDA action date for our ceftolozane/tazobactam NDA; clinical studies investigating SIVEXTRO for the potential treatment of HABP/VABP; our aspirations to achieve a portion of the IDSA’s goal of 10 new antibiotics by 2020; and the level of our financial and personnel commitments towards antibiotic research, development and commercialization, are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others: regulatory developments in the United States, Europe and other foreign countries, including the risk that the FDA may not approve on a timely basis or at all, our NDA for ceftolozane/tazobactam, may not agree with our interpretation of the results from the clinical studies of ceftolozane/tazobactam, or may require additional data, analysis, information or further studies that may not be clinically feasible or financially practicable, and the risk that the FDA may impose post-marketing requirements on SIVEXTRO and that the European Commission may not agree with our interpretation of the results from the clinical studies of SIVEXTRO; the review of our ceftolozane/tazobactam NDA may take longer than anticipated, including as a result of internal FDA constraints; our ability to successfully commercialize SIVEXTRO, including as a result of regulatory authorities’ decisions regarding labeling and other matters, including adverse side effects, that could affect its commercial potential; the acceptance of and demand for new pharmaceutical products; the availability of adequate pricing and reimbursement from third-party payors for SIVEXTRO; competitive risks from current and future therapeutic alternatives to SIVEXTRO and ceftolozane/tazobactam; our ability to maintain and enforce intellectual property protection for SIVEXTRO and ceftolozane/tazobactam; additional clinical trials of SIVEXTRO and ceftolozane/tazobactam, including in HABP/VABP, may produce negative or inconclusive results or may not be initiated or conducted in a timely manner; technical difficulties, excessive costs or other issues relating to the manufacture or supply of SIVEXTRO and ceftolozane/tazobactam, including our ability to work with our third party contract manufacturers that manufacture and supply SIVEXTRO and ceftolozane/tazobactam on our behalf; we may encounter other unanticipated or unexpected risks with respect to the development manufacture or supply of SIVEXTRO and ceftolozane/tazobactam; the fact that drug discovery and development is complex, time consuming, expensive and fraught with a high risk of failure; and those additional factors discussed in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements.

Copyright © Business Wire 2015

Cubist Pharmaceuticals, Inc.
Eileen C. McIntyre, 781-860-8533
Vice President, Investor Relations
Elizabeth Dunavant, 781-860-8680
Director, Product Communications